As the number of asthmatics, COPD, and allergy patients continues to grow, the upper respiratory treatment market is attracting a number of new companies – companies with some novel approaches to the problem of chronic airway inflammation and reactive airway disease. These companies are conducting ongoing research into the way asthma and COPD are diagnosed and measured, minimally invasive techniques to treat airway congestion, and technology improvements focused on systemic delivery of proteins and peptides as well as novel small molecule therapeutics.  New drug classes that focus on molecular targets are emerging as important tools for practitioners. Interest is growing among practitioners and their patients for treatments that are capable of delivering two drugs that can act in concert to mitigate the effects of airway inflammation and reactive airway disease better than a single drug. These combination products pair drugs with different indications to maximize patient relief

Publication Date: March 2008